Injection drug for increasing human sperm production and method for use thereof
SUBSTANCE: invention discloses an injection drug in form of a water-oil suspension of a chimeric protein with water-insoluble enzymatically inactive chloramphenicol acetyltransferase without 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and a somatostatin-14 amino acid sequence AGCFWKTFTSC in refined vegetable oil with addition of apyrogenic water for injection. The invention also relates to a method of increasing human sperm production, which comprises hypodermic injection of said drug twice with an interval of 14-18 days in amount of 50-100 mcg protein per kg body weight.
EFFECT: invention improves reproductive capacity of men by increasing ejaculate volume, sperm count, the percentage of live, active sperm when the injection drug is used with low reactogenicity of the adjuvant, which allows painless injection.
6 cl, 1 tbl
The invention relates to andrology, and specifically to inject the drug to increase spermophobia person and the method of its application. The invention is intended to enhance the reproductive ability of the individual, allowing you to increase the amount of ejaculate and to raise some qualitative characteristics of human sperm.
Modern medical science in several ways solves the problem of increasing ejaculate volume, sperm count in the ejaculate and improve their quality characteristics is the use of hormonal, adaptogenic, herbal preparations. As hormonal therapies aimed at increasing the number of sperm in the ejaculate, using drugs from the group of antiestrogen - clomiphene citrate and preparations based on human chorionic gonadotropin (R.V. Aivanov, NS Parfenova, became popular Kurbatov. Treatment oligospermii in men with infertility. Problems of endocrinology, 2010, No.1, p.31-34).
According to literature data, medical therapy oligospermii are not always successful. In this case, recommend alternative treatments - prescribed drugs-antioxidants, substances containing increased amounts of vitamin C, selenium, folic acid, L-carnitine. According to clinical issledovaniia substances neutralize free radicals and enhances the activity of metabolic processes in sperm a beneficial effect on male fertility. ("Andrology and genital surgery" is a scientific and medical peer-reviewed multidisciplinary journal, Hamidov SR, Tazetdinov OF Results of an open comparative study drugs "Speman and Spiractin" as a means of treatment of idiopathic photosphere. No. 2, 2011, p.61-66.)
Another method of increasing the volume of ejaculate and enhancing qualitative characteristics of human sperm based on the increase in the body concentration of endogenous growth hormone induction of the synthesis automatisation antibodies. This leads to a decrease in the concentration of endogenous somatostatin and enhance the content of the hormone that, in turn, has a stimulating effect on the growth and proliferation of cells in the gonads of the person.
Somatostatin is a biologically active tetradecapeptide produced in the hypothalamus and gastrointestinal tract of mammals. For the first time the biological activity of a substance, later defined as somatostatinoma, was discovered in 1968 by Crusecom. In subsequent from the hypothalamus of animals was selected substance representing low-molecular peptide having the ability to regulate the concentration of growth hormone in animals.
Somatostatin-14 has a strong inhibitory action is the development of a number of hormones (somatotropin, thyroid-stimulating hormone, insulin, glucagon, gastrin, pepsin), triggers the inhibition of the secretion of digestive enzymes, the pancreas, small intestine, slow motility of the gastrointestinal tract and the evacuation of its contents.
The study of amino acid composition of somatostatin various members of the animal Kingdom showed a sufficient degree of homology peptides, synthesized by living organisms at different stages of evolutionary development. Amino acid sequence of somatostatin-14 is identical to living organisms, from fish to mammals and humans.
A wide range of physiological actions of somatostatin-14 and no, unlike growth hormone, species specificity in mammals has been the basis for exploring the possibility of its use to optimize breeding and fattening, raising dairy animal productivity, and increase spermophobia manufacturers of farm animals and chickens.
Method somatostatinomas immune deprived of many of the disadvantages arising from the use of anabolic hormones or recombinant somatotropin. The mechanism of action is based on the temporary binding of endogenous somatostatin-14 specific antisomatostatin antibodies and increase concentric and endogenous growth hormone in physiological limits. However, wide application of the method of active immunization of animals against endogenous somatostatin-14 a long time it was impossible due to its high cost as the main way of obtaining peptide was chemically synthesized, which is economically not allowed to implement this approach in practice. Because of the small size of the somatostatin-14 does not allow its direct microbial synthesis using recombinant DNA technology described several methods of its synthesis in the form of chimeric proteins with subsequent isolation of the target product, not given satisfactory results. The main disadvantage of the above methods is extremely low immunogenicity obtained drugs against somatostatin, due to its masking of the molecule in the chimeric protein, therefore, these methods of producing chimeric proteins did not find wide practical use (R. Itakura et al., 1977. Expression in E. Coli of a chemically synthesized unit gene of hormone somatostatin. Science, 1986, 1056-1063; A.A. Shishkin and other Synthesis fragment somatostatin genes. Chemistry of natural compounds, 1988, No. 6, s-615).
The known method of constructing chimeric somatostatinergic proteins using amino acid spacer containing arginine and Proline, causing localization of somatostatin on the surface of carrier protein and thereby high immuno is a property of the drug (RU 2031121 C1, IPC C12N 15/12, 1995). The design consists of a water-insoluble protein carrier (fragment of bacterial chloramphenicolchloramphenicol without the 10 C-terminal amino acids), tetramer spacer and C-terminal somatostatin-14. The molecular weight of the chimeric protein is 28 kDa. This chimeric protein is expressed by Escherichia coli B-6519 transformed by the plasmid pC(Sp)4 S. Strain deposited in Russian national collection of industrial microorganisms under the number B-6519. Chimeric protein with the exposed somatostatin is a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acid residues, which through spacer elements sequence attached to the amino acid sequence of somatostatin-14. Method antisomatostatin immunization of animals with the use of this chimeric somatostatinergic protein is used in the cattle industry (EN 2034457 C1 IPC A01K 67/02, 1995).
The objective of the invention is to improve the reproductive ability of men by increasing ejaculate volume, sperm count, proportion of live, active motile sperm using the drug for injection with low reactogenicity adjuvant that allows injection without painful the feelings.
The solution to this problem provides an injectable drug to increase spermophobia person in the form of water-in-oil suspensions of the chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC refined vegetable oil with the addition of pyrogen-free water for injection.
The mechanism of drug action based on the temporary blocking activity of endogenous somatostatin person, increased concentrations of somatotropic hormone and increased activity of spermatogenesis.
In the best embodiment, injecting the drug to increase spermophobia person contains a chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC based 200-400 mg of the indicated chimeric protein per 100 ml of refined vegetable oil, comprising 5.0 to 10.0 wt.% pyrogen-free water for injection.
The drug is to increase spermophobia person can contain refined cottonseed oil or refined peanut oil.
The way to increase sperm the production person includes two subcutaneous injections with an interval of 14-18 days the injection of the drug in the form of water-in-oil suspensions of the chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC refined vegetable oil with the addition of pyrogen-free water for injection at the rate of 50-100 μg of protein per 1 kg of body weight.
In the best embodiment of the invention using injectable drug in suspension chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC in the rate of 200-400 mg of the indicated chimeric protein per 100 ml of refined vegetable oil, comprising 5.0 to 10.0 wt.% pyrogen-free water for injection. In the particular case used the drug may contain refined cottonseed oil or refined peanut oil.
The implementation of the invention and efficacy
The possibility of carrying out the invention is illustrated by the example of obtaining injectable drug to increase sperm of a man.
Obtained and purified from the impurities of the drug is protein dissolved in buffer 0.2 M Tris-HCL pH 8.0, containing 6 M guanidinium and 2 M of META (M-EDTA). Add 50-fold molar excess of β-mercaptoethanol in the calculation of the number of S-S GRU is p chimeric protein and the solution is quickly diluted 10-fold volume of buffer without handinhand. The resulting hybrid protein precipitate is separated by centrifugation for 15 minutes at 12000 g and 4°C and freeze-dried for storage or cooking oil-water suspension.
To prepare the finished form of injection drug use refined vegetable oil and pyrogen-free water for injection. In vegetable oil, water is added in amounts of 5-10%. Then add a portion of the dry protein at the rate of 200 mg per 100 ml of water-in-oil suspension. The suspension is homogenized for 1-2 minutes and transfer to the filling equipment. The prepared suspension of the drug Packed in containers (e.g., disposable syringes). Finished dosage form of the preparation is sterilized with ionizing radiation at a total dose of 6 kGy.
When different concentrations of the components of the injectable preparation is prepared similarly. Preferred are the following contents of the components in 95 ml of refined vegetable oil: 200 mg of chimeric protein - 5.0 wt.% apirogennoy water for injection; 400 mg of chimeric protein - 10 wt.% pyrogen-free water for injection.
Use as an adjuvant for such preparation of vegetable oil, fully metabolized in the body, greatly reduce the level of reactogenicity adjuvant isoset necessary conditions for the gradual admission of the active substance in the human body (depot preparation). Can be used on cotton and peanut butter. The presence of pyrogen-free water at the end of the recipe of preparation is justified by the need to obtain a water-in-oil emulsion of the drug.
Efficacy of injectable drug to increase sperm of a man is illustrated by the following example.
In the experimental group included men aged 30-53 years with signs of oligospermia (concentration of spermatozoa in 1 ml of ejaculate ranged from 11 to 15 million cells), ejaculate volume equal to 1.5 and 2.1 ml, the number of actively motile (a) spermatozoa equal to 18-23%. The number of live sperm was on the bottom of the norms and who was 48-53%. Patients did not suffer from diabetes mellitus, hypothyroidism, hyperthyroidism, hypercortisolism, cancer, acute or chronic liver diseases, urological and/or infectious and inflammatory diseases in the acute stage, varicocele.
The generalized results of the laboratory analyses are presented in table 1.
|Estimated figures||sperm||the specified number of days after|
|sperm||before the introduction of||the first injection of the drug,|
|(min-max)||30 days||60 days||90 days|
|Ejaculate volume, ml||1,5-2,1||2,6-2,9||of 3.0-3.5||2,8-3,7|
|The number of spermatozoa in 1||11-15||14-21||18-28||21-34|
|ml of ejaculate, million/ml|
|The share of active mobile||18-23||21-28||23-32||22-41|
|sperm (a), %|
|The percentage of live spermatozoa, %||48-53||52-61||54-68||54-72|
All patients were introduced subcutaneously in the shoulder area of the water-oil suspension somatostatinergic drug in the dose of 50 mg/kg of body weight twice with an interval between injections 14-18 days.
After 30, 60, 90 days after the first injection the patients were put sperm samples and analyzed laboratory values.
Examples of the invention are not exhaustive. Possible other embodiments of the invention, corresponding to the volume of patent claims.
1. Injecting the drug to increase spermophobia person in the form of water-oil is Uspenie chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC refined vegetable oil with the addition of pyrogen-free water for injection.
2. The preparation according to claim 1, characterized in that it contains a chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC based 200-400 mg of the indicated chimeric protein per 100 ml of refined vegetable oil, comprising 5.0 to 10.0 wt.% pyrogen-free water for injection.
3. The preparation according to claim 1 or 2, characterized in that it contains refined cottonseed oil or refined peanut oil.
4. The way to increase spermophobia person, including two subcutaneous injections with an interval of 14-18 days the injection of the drug in the form of water-in-oil suspensions of the chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC refined vegetable oil with the addition of pyrogen-free water for injection at the rate of 50-100 μg of protein per 1 kg of body weight.
5. The method according to claim 4, Otley is audica fact, what use injectable drug in suspension chimeric protein with a water-insoluble enzyme inactive chloramphenicolchloramphenicol without the 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and somatostatin-14 amino acid sequence AGCFWKTFTSC in the rate of 200-400 mg of the indicated chimeric protein per 100 ml of refined vegetable oil, comprising 5.0 to 10.0 wt.% pyrogen-free water for injection.
6. The method according to claim 4 or 5, characterized in that use injectable preparation containing refined cottonseed oil or refined peanut oil.
SUBSTANCE: invention relates to field of biotechnology, in particular to immunogens based on antigenic tau-peptide, and can be used in medicine. Obtained is immunogen, which contains antigenic tau-peptide, consisting of amino acid sequence, selected from SEQ ID NO:6, 8-19, 21-26, 105 and 108-112, covalently bound with immunogenic carrier by means of linker, represented by formula (G)nC, where n equals 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Linker can be located either on C-terminal (peptide -(G)nC), or on N-terminal (C(G)n-peptide) of peptide. Obtained immunogens are used as base for creation of pharmaceutical compositions for treatment of tau-associated neurological disorders.
EFFECT: invention makes it possible to induce immune response against tau autoantigen in efficient way.
12 cl, 10 dwg, 5 tbl, 16 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention discloses an immunogenic composition having an immunogenic activity on serogroup B and C Neisseria meningitidis containing (a) N. meningitidis serogroup C (NmC) oligosaccharide, (b) proteoliposome vesicles of the outer membrane of N.meningitidis (NmB) serogroup B and (c) NmB protein containing and an amino acid sequence presented in the description, or an immunogenic fragment of the above sequence, or a sequence min. 80% identical to the above sequence. The ingredient (a) may be conjugated with a carrier, e.g. with a protein, CRM197, a diphtherial anatoxin or a tetanus anatoxin. The immunogenic composition can contain aluminium hydroxide or MF59 as an adjuvant. What is described is a N.meningitidis serogroup B and C vaccine containing the described immunogenic composition.
EFFECT: using the invention enables preparing the combined vaccine eliciting an immune response on both serogroups of the agent.
6 cl, 4 dwg, 5 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically, to using a chimeric somatostatin-containing protein for improving the reproductive properties of male farm animals and cocks, and may be used in veterinary science. The injection preparation is used in the form of a chimeric protein suspension with water-insoluble enzyme-inactive chloramphenicol acetyltransferase with no 10 C-terminal amino acids, amino acid spacer (Sp)n, wherein n=1, 2, 4, 8 and somatostatin-14 with AGCFWKTFTSC amino acid sequence in the refined vegetable oil with bee wax added at 250-1000 mg of the above chimeric protein per 100 ml of the refined vegetable oil containing 0.9-1.1 wt % of bee wax. The injection preparation is used in cocks and farm animals after achieving the physiological maturity at 50-200 mcg of the protein per 1 kg of a live body weight.
EFFECT: invention enables increasing sperm production: increasing the ejaculate volume and reducing the biologically damaged sperm in farm animals and cocks by using the preparation for injections with a low-reactogenicity adjuvant.
2 cl, 13 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a composition for nicotinic immunonanotherapy containing synthetic nanocarriers having a polymeric surface conjugated with a variety of nicotine residues with the variety of the nicotinic residues on the nanocarrier form an immunogenic surface providing a low affinity, a high-avidity binding of the nicotinic residues to the surfaces of an antigen presenting cell (APC) compared with an antibody binding, and a pharmaceutically acceptable excipient. The invention provides the nanocarriers capable to stimulate an immune response in T-cells and/or B cells and to produce the antinicotin antibodies with the humoral and cellular response to be achieved in the absence of an exogenous adjuvant.
EFFECT: invention provides the absence of the non-specific response on an inflammation caused by an adjuvant.
17 cl, 37 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely biopharmaceutics and may be used for preparing an immunogenic conjugate. That is ensured by: (a) a reaction of serotype 1 purified polysaccharide with an alkaline buffer to prepare serotype 1 partially des-O-acetylated polysaccharide; (b) a reaction of serotype 1 partially des-O-acetylated polysaccharide and a weak acid to produce serotype 1 neutralised partially des-O-acetylated polysaccharide; (c) a reaction of serotype 1 neutralised partially des-O-acetylated polysaccharide and an oxidising agent to prepare serotype 1 activated polysaccharide; (d) mixing of serotype 1 activated polysaccharide and a carrier protein; (d') combined lyophilisation of mixed serotype 1 activated polysaccharide and the carrier protein before a reaction with a reducing agent; (e) reaction of mixed serotype 1 activated polysaccharide and the carrier protein with the reducing agent to prepare a serotype 1 activated polysaccharide/carrier protein conjugate; and (f) capping of unreacted aldehydes in the serotype 1 activated polysaccharide/carrier protein conjugate. What is also presented is a method for preparing a multivalent immunogenic composition.
EFFECT: group of inventions enables preparing the composition presented in the form of vaccines that decreases a number of severe pneumococcal diseases.
27 cl, 17 ex
SUBSTANCE: invention refers to medicine. What is presented is a lyophilised preparation containing at least one nicotine - virus-like particle conjugate, and a stabiliser composition containing at least one nonreducing disaccharide and at least one non-ionic surfactant wherein the pre-lyophilisation pH value of the stabiliser composition makes 5.8 to 6.6, preferentially 6.0 to 6.4.
EFFECT: invention provides producing the effective lyophilised vaccinal preparation able to keep stability for a long period of time.
14 cl, 3 dwg, 4 tbl, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention discloses compositions for inducing an immune response in a patient, containing a combination of two or more monovalent conjugates wherein each of the monovalent conjugates contains a carrier protein N19 conjugated with a saccharide antigen of the serogroups A, C, W135 or Y Neissera meningitides. A molecule of the carrier protein in the monovalent conjugate is preferred to be conjugated with more than one molecule of the saccharide antigen. Besides, the invention discloses a multivalent conjugate for inducing an immune response in a patient, containing two or more antigen-different saccharide antigens of the serogroups A, C, W135 or Y Neissera meningitides conjugated with the carrier protein N19. The compositions may contain one or more said monovalent conjugates and one or more said multivalent conjugates. The invention shows applicability of the multivalent conjugate and compositions in preparing a medicine for enhancing the immune response in a patient.
EFFECT: compositions used under the invention elicit much stronger and fast immune response and exhibit lower reactogenicity for a patient.
16 cl, 33 dwg, 2 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to molecular biology, virology, immunology and medicine. The invention presents a composition which contains a sequenced and repetitive antigen or antigen determinant array, and particularly a composition which contains an Aβ1-6-peptide-HPV conjugate. More specifically, the invention provides the composition which contains a virus-like particle and at least one coupled Aβ1-6-peptide. Also, the invention describes a method for preparing the conjugates and the sequenced and repetitive arrays respectively.
EFFECT: compositions presented in the invention may be applicable for producing vaccines intended for treating Alzheimer's disease, and as pharmaceutical agents intended for preventing or treating Alzheimer's disease and for effective immune response induction, particularly antibody responses; besides, the compositions presented in the invention are established to be applicable first of all for effective induction of autoantigenic responses.
45 cl, 35 dwg, 22 ex
SUBSTANCE: invention refers to medicine and concerns an influenza vaccine and method for preparing it. Substance of the invention involves the influenza vaccine containing the coupling of purified influenza virus antigens and a polymeric carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30, and a method for preparing the influenza vaccine involving the cultivation of influenza virus strain in chicken embryos to produce a purified viral concentrate that is followed by inactivating, splitting the viral concentrate to produce the purified influenza virus antigens and coupling with the polymer carrier representing 2-methyl-5-vinylpyridine and N-vinylpyrrolidone copolymer in proportions 1: 5-30.
EFFECT: preparation of the vaccine.
2 cl, 5 ex, 3 tbl
FIELD: medicine, immunology.
SUBSTANCE: group of inventions relates to medicine in particular to immunology and can be applied to enhance the immune response of animals and human to antigen consisting of one or a number of epitopes; for the above purpose the parenteral immunization of the patient is performed either with the mixture of the above antigen and adjuvant in the shape of spherical particles or with the above antigen fixed on the surface of the spherical particles; at that the spherical particles consist of thermo-denaturated coat protein of spiral plant viruses, predominantly tobacco mosaic virus.
EFFECT: invention secures the efficient stimulation of the immune response to the antigen upon pareneteral immunization of the patient with small doses of the antigen.
2 cl, 9 ex, 9 dwg
SUBSTANCE: the innovation deals with new immunogenic conjugates of beta-propionamide-bound polysaccharide and N-propionamide-bound oligosaccharide with protein, and the method to obtain these conjugates has been suggested, as well. Conjugates should be applied to obtain vaccines against infectious diseases and cancer that enables to broaden the number of preparations applied in treating the above-mentioned diseases.
EFFECT: higher efficiency.
1 dwg, 2 ex, 8 tbl
SUBSTANCE: vaccine is high molecular weight protein conjugate with angiotensine II taken in high molecular weight protein : angiotensine II proportion of 1:12-55 in % by weight. The conjugate is modified with equilibrium quantity of immunocompetent polyelectrolyte like polyoxydonium.
EFFECT: stable physiological response within prolonged period of 6-12 months.
FIELD: organic chemistry, polymers, immunochemistry of high-molecular compounds.
SUBSTANCE: invention describes a synthetic hapten based on copolymers of N-vinylpyrrolidone, crotonic acid and p-crotonoyl aminophenol comprising covalently joined 2-naphthyl amine as a hapten of the following general formula:
wherein m = 88.5 mole%; n = 6.8-10.3 mole%, and l = 1.2-4.7 mole%. Invention provides specificity of antibodies raised against 2-naphthylamin as a hapten and possibility for preparing highly specific antibodies raised against carcinogen 2-naphthylamine as a hapten by immunization of rabbits with synthetic antigen comprising a copolymer of N-vinylpyrrolidone, crotonic acid and p-crotonoyl aminophenol as a macromolecular carrier. Also, invention provides possibility for practice using these antibodies for immunological recording 2-naphthylamine as a hapten in blood of industrial workers subjected for exposition with 2-naphthylamine. The proposed compound elicits antigenic features and can be used for detection of oncological risk among workers subjecting with contact with 2-naphthylamine.
EFFECT: valuable properties of antigen.
1 tbl, 1 dwg, 6 ex
FIELD: medicine, in particular treatment of malignant neoplasm.
SUBSTANCE: claimed method includes administration of vaccine representing complex of heat shock protein and tumor peptide, isolated from subject tumor tissue, and radioactive preparation Oncofer. Oncofer is administered both during vaccination course and after vaccination.
EFFECT: stable antitumor immunity, enhanced tumor cell apoptosis and blocked blood supply due to alteration of erythrocyte properties in tumor caused by radioactive preparation and activation of clot formation in said vessels.
2 cl, 4 ex, 2 dwg
FIELD: medicine, biotechnology.
SUBSTANCE: invention relates to the development of a recombinant fused protein consisting of an oncoprotein E7 VPCH 11 type with a sequence SEQ № 2 and protein of "heat shock" Hsp 70 from M. tuberculosis cells prepared by using plasmid pQE30-E711-dnaK in E. coli cells. The preparation is used against relapsing human papillovirus comprises the recombinant fused protein in the effective amount and a pharmaceutically acceptable carrier. Method for immunotherapy of relapsing larynx papillomatosis involves intracutaneous administration of indicated preparation in a patient. The advantage of invention involves the development of a novel preparation showing improved immunological indices. Proposed preparative formulations can be used in immunotherapy of relapsing larynx papillomatosis in humans.
EFFECT: valuable medicinal properties of protein, improved method for treatment.
3 cl, 6 dwg, 7 ex
FIELD: medicine, oncology, peptides.
SUBSTANCE: invention relates to a chimeric protein used in treatment of malignant lymphomas. Invention proposes chimeric protein consisting of two peptides representing inhibitor of cyclin kinases as an active fragment p16INK4a with amino acid sequence 84-13 or 84-106 as a therapeutic agent and the second peptide VP22 with sequence 140-301 of virus herpes simplex as a transporting agent. Advantage of the invention involves the development of preparation of high effectiveness of penetration into cells and possessing cytostatic and cytotoxic effects.
EFFECT: valuable medicinal properties of chimeric protein.
1 dwg, 2 ex
FIELD: medicine, radiation medicine.
SUBSTANCE: method involves subcutaneous administration of anti-influenza vaccine "Grippol" in the effective dose. Invention provides enhancing effectiveness of body to effect of ionizing radiation. Invention can be used for prophylaxis of radiation damage.
EFFECT: improved method of prophylaxis.
5 tbl, 2 ex
FIELD: chemical-pharmaceutical industry, proteins.
SUBSTANCE: invention concerns to cytokine-containing fused proteins showing the enhanced therapeutic index, and methods for enhancing the therapeutic index of these fused proteins. Fused proteins are able for binding with cytokine receptors of more one type expressed on cells and to bind with cells of more one type also. Except for, fused proteins possess a half-time value in blood stream of a patient as compared with that of corresponding natural cytokines.
EFFECT: improved and valuable properties of cytokines.
21 cl, 3 tbl, 11 ex
SUBSTANCE: method involves carrying out single-stage conjugate synthesis having stereospecific (affine) compound conjugated in covalent way to suspensoid carbon particles.
EFFECT: enabled direct analyte observation on solid phase surface as back spots; increased sensitivity of diagnosticum for performing immunochemical, gene-hybridizing and ligand-receptor studies and creating instrumentless rapid diagnosis test systems.
FIELD: chemical and pharmaceutical industry.
SUBSTANCE: invention relates to lyophilized pharmaceutical immunocytokine composition including immunocytokine and containing as cytokine component interleukin-2 (IL-2), sugar or aminosugar, amino acid and surfactant, wherein said composition contains: immunocytokines from 0.1 to 25 mg/ml; sugar or aminosugar 1-200 mg/ml; amino acid 1-200 mMol/l; and surfactant 0.001-1 mass %.
EFFECT: composition for parantheral administering with prolonged storage time even at increased temperatures.
13 cl, 8 ex, 4 tbl, 2 dwg